Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2020-12-10 Merger & Acquisition
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
8-K/A
Merger & Acquisition Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a previously filed Form 8-K. It includes historical financial statements of an acquired company (Pfenex Inc.) and pro forma financial information related to the acquisition. The document references the acquisition and merger agreement, and provides audited financial statements and pro forma combined financials as exhibits. This type of filing is related to merger and acquisition activity, specifically providing financial disclosures required by SEC rules for business combinations. The presence of pro forma financials and acquisition details aligns with M&A activity filings rather than a full annual report or other categories. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length (5169 characters) and content confirm it is the actual filing with substantive financial data, not just an announcement or certification.
2020-12-10 English
PRIMARY DOCUMENT
Director's Dealing
2020-12-10 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the completion of a sale transaction of a subsidiary business (Vernalis Business) by Ligand Pharmaceuticals. It details the transaction terms, including cash payment and future receipts, and includes forward-looking statements. There are no financial statements or detailed financial performance data included, nor is this an earnings release or annual/interim report. The document is an announcement of a significant transaction event, which fits best under Capital/Financing Update (CAP) as it relates to a sale of business assets and capital structure impact. The document length is over 5,000 characters and contains substantive information about the transaction, not just a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the most appropriate classification is CAP with high confidence.
2020-12-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes clinical and regulatory progress updates, milestone payments, and forward-looking statements related to Ligand Pharmaceuticals' OmniAb platform and partnerships. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. It is not an earnings release, proxy statement, or management discussion. The document is a regulatory filing reporting significant events but not a full report or presentation. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length (6796 characters) and content confirm it is a substantive announcement rather than a brief report publication announcement or certification.
2020-11-23 English
DEF 14A
Proxy Solicitation & Information Statement
2020-11-12 English
PRIMARY DOCUMENT
Director's Dealing
2020-11-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.